US-based health firm Boston Scientific buys Penumbra for $14.5B

​​​​​​​By Gokhan Ergocun

ISTANBUL (AA) - US-based health technologies firm Boston Scientific Corporation announced Thursday that it bought the Penumbra medical firm for $14.5 billion

The transaction values each Penumbra share at $374, with Penumbra stockholders having the right to elect to receive $374 in cash.

The total transaction consideration is paid approximately 73% in cash and 27% in shares of Boston Scientific common stock.

The transaction is expected to be completed in 2026.

The statement said cardiovascular diseases are the leading cause of death globally and include disorders of the heart and blood vessels that can restrict blood flow and increase the risk of clots throughout the body.

"To address the escalating prevalence of these complex diseases, Penumbra has developed a comprehensive portfolio that includes differentiated devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms," it added.

Penumbra offers innovative mechanical thrombectomy products for use in peripheral vascular procedures to remove blood clots causing blockages in arterial, venous and pulmonary vessels, it noted.